Once-daily etravirine/raltegravir (400/800 mg q24h) dual therapy maintains viral suppression over 48 weeks in HIV-infected patients switching from a twice-daily etravirine/raltegravir (200/400 mg q12h) regimen
Abstract Background Etravirine/raltegravir dual therapy has been shown to be highly effective as a twice-daily (q12h) regimen in suppressed HIV-infected patients enrolled in the ANRS-163 study. Objectives As a once-daily (q24h) regimen is easier for daily life, we aimed to evaluate the capacity of e...
Gespeichert in:
| Veröffentlicht in: | Journal of antimicrobial chemotherapy 2021-01, Vol.76 (2), p.477-481 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 481 |
|---|---|
| container_issue | 2 |
| container_start_page | 477 |
| container_title | Journal of antimicrobial chemotherapy |
| container_volume | 76 |
| creator | Palich, Romain Allavena, Clotilde Peytavin, Gilles Soulie, Cathia Tubiana, Roland Weiss, Laurence Montoya Ferrer, Ana Duvivier, Claudine Bouchaud, Olivier Bottero, Julie Durand, Aurore Lê, Minh-Patrick Marcelin, Anne-Geneviève Dudoit, Yasmine Assoumou, Lambert Katlama, Christine |
| description | Abstract
Background
Etravirine/raltegravir dual therapy has been shown to be highly effective as a twice-daily (q12h) regimen in suppressed HIV-infected patients enrolled in the ANRS-163 study.
Objectives
As a once-daily (q24h) regimen is easier for daily life, we aimed to evaluate the capacity of etravirine/raltegravir (400/800 mg) q24h to maintain viral suppression in patients on etravirine/raltegravir q12h.
Methods
Patients on a suppressive etravirine/raltegravir q12h regimen for at least 96 weeks were switched to etravirine/raltegravir q24h in this prospective, multicentre, open-label, single-arm study. Primary outcome was the rate of virological failure (VF: confirmed pVL >50 copies/mL, single pVL >400 copies/mL or single pVL >50 copies/mL with ART change) at Week 48 (W48). Secondary outcomes included treatment strategy success rate (no VF and no treatment discontinuation), regimen tolerability, plasma drug concentrations and resistance profile in the case of VF.
Results
A total of 111 patients were enrolled, with a median (IQR) age of 57 years (52–62), CD4 count of 710 cells/mm3 (501–919) and viral suppression for 7.9 years (5.9–10.7). Two patients experienced viral rebound at W24 and W48, leading to a VF rate of 2.0% (95% CI 0.5–7.8) at W48, associated with INSTI resistance in one case. Both had past NNRTI mutations. Ten patients discontinued treatment for adverse events (n = 2), investigator or patient decisions (n = 3), lost to follow-up (n = 3), death (n = 1) or pregnancy (n = 1). Overall, the strategy success rate was 89% (95% CI 81.5–93.6) at W48. In a subgroup of 64 patients, median (IQR) plasma C24h concentrations were 401 ng/mL (280–603) for etravirine and 62 ng/mL (31–140) for raltegravir.
Conclusions
Switching patients virally suppressed on etravirine/raltegravir q12h to the same regimen but given q24h was highly effective in maintaining virological suppression in HIV-infected patients. |
| doi_str_mv | 10.1093/jac/dkaa423 |
| format | Article |
| fullrecord | <record><control><sourceid>oup_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_03177872v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/jac/dkaa423</oup_id><sourcerecordid>10.1093/jac/dkaa423</sourcerecordid><originalsourceid>FETCH-LOGICAL-c349t-10a87baed0d9c0cc8a92a373830a6fc1d62e54aad95da79cadc5d52c6ac508453</originalsourceid><addsrcrecordid>eNqFkU9rGzEQxUVpaZy0p96LTqWhbDxaaXe1xxCaOmDIJel1mUiztpL9V0m28cfsN6oSuzm2h2GYx2-GxzzGPgm4EFDL-SOauX1CVLl8w2ZClZDlUIu3bAYSiqxShTxhpyE8AkBZlPo9O5ES6rqUesZ-3w6GMouu23OKHrfOu4HmHrtIq5eRf1UAcw3A-xX_lav1Obcb7Hhck8dpz3t0Q0wVeIKTHjbT5CkENw583JLnSvMd0VPgbuCLm5-ZG1oykSyfMDoaYuBh56JZu2HFWz_2HHncuf-6ypMrdXQl8uTK08r1NHxg71rsAn089jN2f_397mqRLW9_3FxdLjMjVR0zAairByQLtjZgjMY6R1lJLQHL1ghb5lQoRFsXFqvaoDWFLXJToilAp5-esfPD3TV2zeRdj37fjOiaxeWyedZAiqrSVb4Vif12YI0fQ_DUvi4IaJ5DbFKIzTHERH8-0NPmoSf7yv5NLQFfDsC4mf556Q9sQ6dW</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Once-daily etravirine/raltegravir (400/800 mg q24h) dual therapy maintains viral suppression over 48 weeks in HIV-infected patients switching from a twice-daily etravirine/raltegravir (200/400 mg q12h) regimen</title><source>MEDLINE</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><source>Free Full-Text Journals in Chemistry</source><creator>Palich, Romain ; Allavena, Clotilde ; Peytavin, Gilles ; Soulie, Cathia ; Tubiana, Roland ; Weiss, Laurence ; Montoya Ferrer, Ana ; Duvivier, Claudine ; Bouchaud, Olivier ; Bottero, Julie ; Durand, Aurore ; Lê, Minh-Patrick ; Marcelin, Anne-Geneviève ; Dudoit, Yasmine ; Assoumou, Lambert ; Katlama, Christine</creator><creatorcontrib>Palich, Romain ; Allavena, Clotilde ; Peytavin, Gilles ; Soulie, Cathia ; Tubiana, Roland ; Weiss, Laurence ; Montoya Ferrer, Ana ; Duvivier, Claudine ; Bouchaud, Olivier ; Bottero, Julie ; Durand, Aurore ; Lê, Minh-Patrick ; Marcelin, Anne-Geneviève ; Dudoit, Yasmine ; Assoumou, Lambert ; Katlama, Christine ; ETRAL QD study group ; the ETRAL QD study group</creatorcontrib><description>Abstract
Background
Etravirine/raltegravir dual therapy has been shown to be highly effective as a twice-daily (q12h) regimen in suppressed HIV-infected patients enrolled in the ANRS-163 study.
Objectives
As a once-daily (q24h) regimen is easier for daily life, we aimed to evaluate the capacity of etravirine/raltegravir (400/800 mg) q24h to maintain viral suppression in patients on etravirine/raltegravir q12h.
Methods
Patients on a suppressive etravirine/raltegravir q12h regimen for at least 96 weeks were switched to etravirine/raltegravir q24h in this prospective, multicentre, open-label, single-arm study. Primary outcome was the rate of virological failure (VF: confirmed pVL >50 copies/mL, single pVL >400 copies/mL or single pVL >50 copies/mL with ART change) at Week 48 (W48). Secondary outcomes included treatment strategy success rate (no VF and no treatment discontinuation), regimen tolerability, plasma drug concentrations and resistance profile in the case of VF.
Results
A total of 111 patients were enrolled, with a median (IQR) age of 57 years (52–62), CD4 count of 710 cells/mm3 (501–919) and viral suppression for 7.9 years (5.9–10.7). Two patients experienced viral rebound at W24 and W48, leading to a VF rate of 2.0% (95% CI 0.5–7.8) at W48, associated with INSTI resistance in one case. Both had past NNRTI mutations. Ten patients discontinued treatment for adverse events (n = 2), investigator or patient decisions (n = 3), lost to follow-up (n = 3), death (n = 1) or pregnancy (n = 1). Overall, the strategy success rate was 89% (95% CI 81.5–93.6) at W48. In a subgroup of 64 patients, median (IQR) plasma C24h concentrations were 401 ng/mL (280–603) for etravirine and 62 ng/mL (31–140) for raltegravir.
Conclusions
Switching patients virally suppressed on etravirine/raltegravir q12h to the same regimen but given q24h was highly effective in maintaining virological suppression in HIV-infected patients.</description><identifier>ISSN: 0305-7453</identifier><identifier>EISSN: 1460-2091</identifier><identifier>DOI: 10.1093/jac/dkaa423</identifier><identifier>PMID: 33099638</identifier><language>eng</language><publisher>England: Oxford University Press</publisher><subject>Anti-HIV Agents - therapeutic use ; HIV Infections - drug therapy ; HIV-1 ; Human health and pathology ; Humans ; Infectious diseases ; Life Sciences ; Middle Aged ; Nitriles ; Prospective Studies ; Pyrimidines ; Raltegravir Potassium - therapeutic use ; Treatment Outcome ; Viral Load</subject><ispartof>Journal of antimicrobial chemotherapy, 2021-01, Vol.76 (2), p.477-481</ispartof><rights>The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: journals.permissions@oup.com. 2021</rights><rights>The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: journals.permissions@oup.com.</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c349t-10a87baed0d9c0cc8a92a373830a6fc1d62e54aad95da79cadc5d52c6ac508453</cites><orcidid>0000-0002-4670-8288 ; 0000-0002-4359-537X ; 0000-0003-1010-1270 ; 0000-0001-6949-3630 ; 0000-0003-0047-0101</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,1584,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33099638$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.sorbonne-universite.fr/hal-03177872$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Palich, Romain</creatorcontrib><creatorcontrib>Allavena, Clotilde</creatorcontrib><creatorcontrib>Peytavin, Gilles</creatorcontrib><creatorcontrib>Soulie, Cathia</creatorcontrib><creatorcontrib>Tubiana, Roland</creatorcontrib><creatorcontrib>Weiss, Laurence</creatorcontrib><creatorcontrib>Montoya Ferrer, Ana</creatorcontrib><creatorcontrib>Duvivier, Claudine</creatorcontrib><creatorcontrib>Bouchaud, Olivier</creatorcontrib><creatorcontrib>Bottero, Julie</creatorcontrib><creatorcontrib>Durand, Aurore</creatorcontrib><creatorcontrib>Lê, Minh-Patrick</creatorcontrib><creatorcontrib>Marcelin, Anne-Geneviève</creatorcontrib><creatorcontrib>Dudoit, Yasmine</creatorcontrib><creatorcontrib>Assoumou, Lambert</creatorcontrib><creatorcontrib>Katlama, Christine</creatorcontrib><creatorcontrib>ETRAL QD study group</creatorcontrib><creatorcontrib>the ETRAL QD study group</creatorcontrib><title>Once-daily etravirine/raltegravir (400/800 mg q24h) dual therapy maintains viral suppression over 48 weeks in HIV-infected patients switching from a twice-daily etravirine/raltegravir (200/400 mg q12h) regimen</title><title>Journal of antimicrobial chemotherapy</title><addtitle>J Antimicrob Chemother</addtitle><description>Abstract
Background
Etravirine/raltegravir dual therapy has been shown to be highly effective as a twice-daily (q12h) regimen in suppressed HIV-infected patients enrolled in the ANRS-163 study.
Objectives
As a once-daily (q24h) regimen is easier for daily life, we aimed to evaluate the capacity of etravirine/raltegravir (400/800 mg) q24h to maintain viral suppression in patients on etravirine/raltegravir q12h.
Methods
Patients on a suppressive etravirine/raltegravir q12h regimen for at least 96 weeks were switched to etravirine/raltegravir q24h in this prospective, multicentre, open-label, single-arm study. Primary outcome was the rate of virological failure (VF: confirmed pVL >50 copies/mL, single pVL >400 copies/mL or single pVL >50 copies/mL with ART change) at Week 48 (W48). Secondary outcomes included treatment strategy success rate (no VF and no treatment discontinuation), regimen tolerability, plasma drug concentrations and resistance profile in the case of VF.
Results
A total of 111 patients were enrolled, with a median (IQR) age of 57 years (52–62), CD4 count of 710 cells/mm3 (501–919) and viral suppression for 7.9 years (5.9–10.7). Two patients experienced viral rebound at W24 and W48, leading to a VF rate of 2.0% (95% CI 0.5–7.8) at W48, associated with INSTI resistance in one case. Both had past NNRTI mutations. Ten patients discontinued treatment for adverse events (n = 2), investigator or patient decisions (n = 3), lost to follow-up (n = 3), death (n = 1) or pregnancy (n = 1). Overall, the strategy success rate was 89% (95% CI 81.5–93.6) at W48. In a subgroup of 64 patients, median (IQR) plasma C24h concentrations were 401 ng/mL (280–603) for etravirine and 62 ng/mL (31–140) for raltegravir.
Conclusions
Switching patients virally suppressed on etravirine/raltegravir q12h to the same regimen but given q24h was highly effective in maintaining virological suppression in HIV-infected patients.</description><subject>Anti-HIV Agents - therapeutic use</subject><subject>HIV Infections - drug therapy</subject><subject>HIV-1</subject><subject>Human health and pathology</subject><subject>Humans</subject><subject>Infectious diseases</subject><subject>Life Sciences</subject><subject>Middle Aged</subject><subject>Nitriles</subject><subject>Prospective Studies</subject><subject>Pyrimidines</subject><subject>Raltegravir Potassium - therapeutic use</subject><subject>Treatment Outcome</subject><subject>Viral Load</subject><issn>0305-7453</issn><issn>1460-2091</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkU9rGzEQxUVpaZy0p96LTqWhbDxaaXe1xxCaOmDIJel1mUiztpL9V0m28cfsN6oSuzm2h2GYx2-GxzzGPgm4EFDL-SOauX1CVLl8w2ZClZDlUIu3bAYSiqxShTxhpyE8AkBZlPo9O5ES6rqUesZ-3w6GMouu23OKHrfOu4HmHrtIq5eRf1UAcw3A-xX_lav1Obcb7Hhck8dpz3t0Q0wVeIKTHjbT5CkENw583JLnSvMd0VPgbuCLm5-ZG1oykSyfMDoaYuBh56JZu2HFWz_2HHncuf-6ypMrdXQl8uTK08r1NHxg71rsAn089jN2f_397mqRLW9_3FxdLjMjVR0zAairByQLtjZgjMY6R1lJLQHL1ghb5lQoRFsXFqvaoDWFLXJToilAp5-esfPD3TV2zeRdj37fjOiaxeWyedZAiqrSVb4Vif12YI0fQ_DUvi4IaJ5DbFKIzTHERH8-0NPmoSf7yv5NLQFfDsC4mf556Q9sQ6dW</recordid><startdate>20210119</startdate><enddate>20210119</enddate><creator>Palich, Romain</creator><creator>Allavena, Clotilde</creator><creator>Peytavin, Gilles</creator><creator>Soulie, Cathia</creator><creator>Tubiana, Roland</creator><creator>Weiss, Laurence</creator><creator>Montoya Ferrer, Ana</creator><creator>Duvivier, Claudine</creator><creator>Bouchaud, Olivier</creator><creator>Bottero, Julie</creator><creator>Durand, Aurore</creator><creator>Lê, Minh-Patrick</creator><creator>Marcelin, Anne-Geneviève</creator><creator>Dudoit, Yasmine</creator><creator>Assoumou, Lambert</creator><creator>Katlama, Christine</creator><general>Oxford University Press</general><general>Oxford University Press (OUP)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>1XC</scope><scope>VOOES</scope><orcidid>https://orcid.org/0000-0002-4670-8288</orcidid><orcidid>https://orcid.org/0000-0002-4359-537X</orcidid><orcidid>https://orcid.org/0000-0003-1010-1270</orcidid><orcidid>https://orcid.org/0000-0001-6949-3630</orcidid><orcidid>https://orcid.org/0000-0003-0047-0101</orcidid></search><sort><creationdate>20210119</creationdate><title>Once-daily etravirine/raltegravir (400/800 mg q24h) dual therapy maintains viral suppression over 48 weeks in HIV-infected patients switching from a twice-daily etravirine/raltegravir (200/400 mg q12h) regimen</title><author>Palich, Romain ; Allavena, Clotilde ; Peytavin, Gilles ; Soulie, Cathia ; Tubiana, Roland ; Weiss, Laurence ; Montoya Ferrer, Ana ; Duvivier, Claudine ; Bouchaud, Olivier ; Bottero, Julie ; Durand, Aurore ; Lê, Minh-Patrick ; Marcelin, Anne-Geneviève ; Dudoit, Yasmine ; Assoumou, Lambert ; Katlama, Christine</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c349t-10a87baed0d9c0cc8a92a373830a6fc1d62e54aad95da79cadc5d52c6ac508453</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Anti-HIV Agents - therapeutic use</topic><topic>HIV Infections - drug therapy</topic><topic>HIV-1</topic><topic>Human health and pathology</topic><topic>Humans</topic><topic>Infectious diseases</topic><topic>Life Sciences</topic><topic>Middle Aged</topic><topic>Nitriles</topic><topic>Prospective Studies</topic><topic>Pyrimidines</topic><topic>Raltegravir Potassium - therapeutic use</topic><topic>Treatment Outcome</topic><topic>Viral Load</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Palich, Romain</creatorcontrib><creatorcontrib>Allavena, Clotilde</creatorcontrib><creatorcontrib>Peytavin, Gilles</creatorcontrib><creatorcontrib>Soulie, Cathia</creatorcontrib><creatorcontrib>Tubiana, Roland</creatorcontrib><creatorcontrib>Weiss, Laurence</creatorcontrib><creatorcontrib>Montoya Ferrer, Ana</creatorcontrib><creatorcontrib>Duvivier, Claudine</creatorcontrib><creatorcontrib>Bouchaud, Olivier</creatorcontrib><creatorcontrib>Bottero, Julie</creatorcontrib><creatorcontrib>Durand, Aurore</creatorcontrib><creatorcontrib>Lê, Minh-Patrick</creatorcontrib><creatorcontrib>Marcelin, Anne-Geneviève</creatorcontrib><creatorcontrib>Dudoit, Yasmine</creatorcontrib><creatorcontrib>Assoumou, Lambert</creatorcontrib><creatorcontrib>Katlama, Christine</creatorcontrib><creatorcontrib>ETRAL QD study group</creatorcontrib><creatorcontrib>the ETRAL QD study group</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>Hyper Article en Ligne (HAL) (Open Access)</collection><jtitle>Journal of antimicrobial chemotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Palich, Romain</au><au>Allavena, Clotilde</au><au>Peytavin, Gilles</au><au>Soulie, Cathia</au><au>Tubiana, Roland</au><au>Weiss, Laurence</au><au>Montoya Ferrer, Ana</au><au>Duvivier, Claudine</au><au>Bouchaud, Olivier</au><au>Bottero, Julie</au><au>Durand, Aurore</au><au>Lê, Minh-Patrick</au><au>Marcelin, Anne-Geneviève</au><au>Dudoit, Yasmine</au><au>Assoumou, Lambert</au><au>Katlama, Christine</au><aucorp>ETRAL QD study group</aucorp><aucorp>the ETRAL QD study group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Once-daily etravirine/raltegravir (400/800 mg q24h) dual therapy maintains viral suppression over 48 weeks in HIV-infected patients switching from a twice-daily etravirine/raltegravir (200/400 mg q12h) regimen</atitle><jtitle>Journal of antimicrobial chemotherapy</jtitle><addtitle>J Antimicrob Chemother</addtitle><date>2021-01-19</date><risdate>2021</risdate><volume>76</volume><issue>2</issue><spage>477</spage><epage>481</epage><pages>477-481</pages><issn>0305-7453</issn><eissn>1460-2091</eissn><abstract>Abstract
Background
Etravirine/raltegravir dual therapy has been shown to be highly effective as a twice-daily (q12h) regimen in suppressed HIV-infected patients enrolled in the ANRS-163 study.
Objectives
As a once-daily (q24h) regimen is easier for daily life, we aimed to evaluate the capacity of etravirine/raltegravir (400/800 mg) q24h to maintain viral suppression in patients on etravirine/raltegravir q12h.
Methods
Patients on a suppressive etravirine/raltegravir q12h regimen for at least 96 weeks were switched to etravirine/raltegravir q24h in this prospective, multicentre, open-label, single-arm study. Primary outcome was the rate of virological failure (VF: confirmed pVL >50 copies/mL, single pVL >400 copies/mL or single pVL >50 copies/mL with ART change) at Week 48 (W48). Secondary outcomes included treatment strategy success rate (no VF and no treatment discontinuation), regimen tolerability, plasma drug concentrations and resistance profile in the case of VF.
Results
A total of 111 patients were enrolled, with a median (IQR) age of 57 years (52–62), CD4 count of 710 cells/mm3 (501–919) and viral suppression for 7.9 years (5.9–10.7). Two patients experienced viral rebound at W24 and W48, leading to a VF rate of 2.0% (95% CI 0.5–7.8) at W48, associated with INSTI resistance in one case. Both had past NNRTI mutations. Ten patients discontinued treatment for adverse events (n = 2), investigator or patient decisions (n = 3), lost to follow-up (n = 3), death (n = 1) or pregnancy (n = 1). Overall, the strategy success rate was 89% (95% CI 81.5–93.6) at W48. In a subgroup of 64 patients, median (IQR) plasma C24h concentrations were 401 ng/mL (280–603) for etravirine and 62 ng/mL (31–140) for raltegravir.
Conclusions
Switching patients virally suppressed on etravirine/raltegravir q12h to the same regimen but given q24h was highly effective in maintaining virological suppression in HIV-infected patients.</abstract><cop>England</cop><pub>Oxford University Press</pub><pmid>33099638</pmid><doi>10.1093/jac/dkaa423</doi><tpages>5</tpages><orcidid>https://orcid.org/0000-0002-4670-8288</orcidid><orcidid>https://orcid.org/0000-0002-4359-537X</orcidid><orcidid>https://orcid.org/0000-0003-1010-1270</orcidid><orcidid>https://orcid.org/0000-0001-6949-3630</orcidid><orcidid>https://orcid.org/0000-0003-0047-0101</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0305-7453 |
| ispartof | Journal of antimicrobial chemotherapy, 2021-01, Vol.76 (2), p.477-481 |
| issn | 0305-7453 1460-2091 |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_hal_03177872v1 |
| source | MEDLINE; Oxford University Press Journals All Titles (1996-Current); EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection; Free Full-Text Journals in Chemistry |
| subjects | Anti-HIV Agents - therapeutic use HIV Infections - drug therapy HIV-1 Human health and pathology Humans Infectious diseases Life Sciences Middle Aged Nitriles Prospective Studies Pyrimidines Raltegravir Potassium - therapeutic use Treatment Outcome Viral Load |
| title | Once-daily etravirine/raltegravir (400/800 mg q24h) dual therapy maintains viral suppression over 48 weeks in HIV-infected patients switching from a twice-daily etravirine/raltegravir (200/400 mg q12h) regimen |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-18T22%3A14%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-oup_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Once-daily%20etravirine/raltegravir%20(400/800%20mg%20q24h)%20dual%20therapy%20maintains%20viral%20suppression%20over%2048%20weeks%20in%20HIV-infected%20patients%20switching%20from%20a%20twice-daily%20etravirine/raltegravir%20(200/400%20mg%20q12h)%20regimen&rft.jtitle=Journal%20of%20antimicrobial%20chemotherapy&rft.au=Palich,%20Romain&rft.aucorp=ETRAL%20QD%20study%20group&rft.date=2021-01-19&rft.volume=76&rft.issue=2&rft.spage=477&rft.epage=481&rft.pages=477-481&rft.issn=0305-7453&rft.eissn=1460-2091&rft_id=info:doi/10.1093/jac/dkaa423&rft_dat=%3Coup_hal_p%3E10.1093/jac/dkaa423%3C/oup_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/33099638&rft_oup_id=10.1093/jac/dkaa423&rfr_iscdi=true |